Piacentini Luca, Chiesa Mattia, Colombo Gualtiero Ivanoe
Immunology and Functional Genomics Unit, Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.
Biomedicines. 2020 Aug 14;8(8):288. doi: 10.3390/biomedicines8080288.
The lack of medical therapy to treat abdominal aortic aneurysm (AAA) stems from our inadequate understanding of the mechanisms underlying AAA pathogenesis. To date, the only available treatment option relies on surgical intervention, which aims to prevent AAA rupture. Identifying specific regulators of pivotal pathogenetic mechanisms would allow the development of novel treatments. With this work, we sought to identify regulatory factors associated with co-expressed genes characterizing the diseased perivascular adipose tissue (PVAT) of AAA patients, which is crucially involved in AAA pathogenesis. We applied a reverse engineering approach to identify cis-regulatory elements of diseased PVAT genes, the associated transcription factors, and upstream regulators. Finally, by analyzing the topological properties of the reconstructed regulatory disease network, we prioritized putative targets for AAA interference treatment options. Overall, we identified NFKB1, SPIB, and TBP as the most relevant transcription factors, as well as MAPK1 and GSKB3 protein kinases and RXRA nuclear receptor as key upstream regulators. We showed that these factors could regulate different co-expressed gene subsets in AAA PVAT, specifically associated with both innate and antigen-driven immune response pathways. Inhibition of these factors may represent a novel option for the development of efficient immunomodulatory strategies to treat AAA.
缺乏治疗腹主动脉瘤(AAA)的医学疗法源于我们对AAA发病机制背后的机制理解不足。迄今为止,唯一可用的治疗选择依赖于手术干预,其目的是预防AAA破裂。识别关键发病机制的特定调节因子将有助于开发新的治疗方法。通过这项工作,我们试图识别与AAA患者患病血管周围脂肪组织(PVAT)特征性共表达基因相关的调节因子,PVAT在AAA发病机制中起着关键作用。我们应用逆向工程方法来识别患病PVAT基因的顺式调节元件、相关转录因子和上游调节因子。最后,通过分析重建的调节疾病网络的拓扑特性,我们确定了AAA干预治疗方案的潜在靶点优先级。总体而言,我们确定NFKB1、SPIB和TBP为最相关的转录因子,以及MAPK1和GSKB3蛋白激酶和RXRA核受体为关键上游调节因子。我们表明,这些因子可以调节AAA PVAT中不同的共表达基因子集,特别是与先天免疫和抗原驱动的免疫反应途径相关的子集。抑制这些因子可能代表开发治疗AAA的有效免疫调节策略的新选择。